A New Jersey federal district court judge shot down pharmaceutical company Novo Nordisk’s legal challenge against the Medicare drug price negotiation program Wednesday (July 31), rejecting, among other claims challenging the constitutionality of the Inflation Reduction Act, the company’s ultra vires claim that CMS went against statutory text in negotiating new maximum fair prices for more than one of its insulin products.